Hong-Kai Cai, Lin Jiang, Jian-Bin Gong, Wen-da Luo, Xia-Yin Zhu
{"title":"淋巴细胞相关比率、c反应蛋白与骨髓增生异常综合征预后价值的关系","authors":"Hong-Kai Cai, Lin Jiang, Jian-Bin Gong, Wen-da Luo, Xia-Yin Zhu","doi":"10.1080/16078454.2025.2538950","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study was designed to investigate the relationship between peripheral blood inflammatory markers and prognosis in MDS patients.</p><p><strong>Methods: </strong>We conducted a study involving 183 MDS patients who were diagnosed at Taizhou Hospital of Zhejiang Province and Enze Hospital between January 2015 and December 2019. The end point of follow-up was September 2022. To minimize the impact of other confounding factors among the 110 included MDS patients, X-tile software was used to determine the optimal cutoff points for peripheral blood inflammation markers. Based on these cutoff points, the cohort of patients was divided into a high-risk group and a low-risk group. The OS in each group was analyzed by the Kaplan-Meier method, and univariate and multivariate Cox regression analyses were employed.</p><p><strong>Results: </strong>The MDS patients included 73 men and 37 women with a median age of 72 years (32-92 years). The median OS was 28 months (1-83 months), 17 patients (15.45%) experienced conversion to AML, and 94 patients (85.45%) died during the follow-up period. The optimal cutoff points were ALC (1.2 × 10<sup>9</sup>/L), AMC (0 × 10<sup>9</sup>/L), CRP (6.1 mg/L), MLR (0.125), NLR (2.25) and PLR (71.4). Patients in the ALC (≤1.2 × 10<sup>9</sup>/L, <i>P</i> = 0.017), MLR (>0.125, <i>P</i> = 0.01), PLR (>71.43, <i>P</i> = 0.044), and CRP (>6.1 mg/L, <i>P</i> < 0.0001) groups had shorter overall survival. The MLR (>0.125, <i>P</i> = 0.011) and CRP (>6.1 mg/L, <i>P</i> = 0.017) levels were related to poor prognosis.</p><p><strong>Conclusions: </strong>Elevated MLR and CRP levels may be independent indicators of poor prognosis in newly diagnosed MDS patients.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"30 1","pages":"2538950"},"PeriodicalIF":1.6000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between lymphocyte-associated ratios, C-reactive protein and prognostic value in myelodysplastic syndromes.\",\"authors\":\"Hong-Kai Cai, Lin Jiang, Jian-Bin Gong, Wen-da Luo, Xia-Yin Zhu\",\"doi\":\"10.1080/16078454.2025.2538950\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study was designed to investigate the relationship between peripheral blood inflammatory markers and prognosis in MDS patients.</p><p><strong>Methods: </strong>We conducted a study involving 183 MDS patients who were diagnosed at Taizhou Hospital of Zhejiang Province and Enze Hospital between January 2015 and December 2019. The end point of follow-up was September 2022. To minimize the impact of other confounding factors among the 110 included MDS patients, X-tile software was used to determine the optimal cutoff points for peripheral blood inflammation markers. Based on these cutoff points, the cohort of patients was divided into a high-risk group and a low-risk group. The OS in each group was analyzed by the Kaplan-Meier method, and univariate and multivariate Cox regression analyses were employed.</p><p><strong>Results: </strong>The MDS patients included 73 men and 37 women with a median age of 72 years (32-92 years). The median OS was 28 months (1-83 months), 17 patients (15.45%) experienced conversion to AML, and 94 patients (85.45%) died during the follow-up period. The optimal cutoff points were ALC (1.2 × 10<sup>9</sup>/L), AMC (0 × 10<sup>9</sup>/L), CRP (6.1 mg/L), MLR (0.125), NLR (2.25) and PLR (71.4). Patients in the ALC (≤1.2 × 10<sup>9</sup>/L, <i>P</i> = 0.017), MLR (>0.125, <i>P</i> = 0.01), PLR (>71.43, <i>P</i> = 0.044), and CRP (>6.1 mg/L, <i>P</i> < 0.0001) groups had shorter overall survival. The MLR (>0.125, <i>P</i> = 0.011) and CRP (>6.1 mg/L, <i>P</i> = 0.017) levels were related to poor prognosis.</p><p><strong>Conclusions: </strong>Elevated MLR and CRP levels may be independent indicators of poor prognosis in newly diagnosed MDS patients.</p>\",\"PeriodicalId\":13161,\"journal\":{\"name\":\"Hematology\",\"volume\":\"30 1\",\"pages\":\"2538950\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/16078454.2025.2538950\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2025.2538950","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：探讨MDS患者外周血炎症标志物与预后的关系。方法：对2015年1月至2019年12月在浙江省台州市医院和恩泽医院诊断的183例MDS患者进行研究。随访结束时间为2022年9月。为了最大限度地减少110例MDS患者中其他混杂因素的影响，使用X-tile软件确定外周血炎症标志物的最佳截止点。根据这些截止点，将患者队列分为高危组和低危组。采用Kaplan-Meier法分析各组OS，采用单因素和多因素Cox回归分析。结果：MDS患者男性73例，女性37例，中位年龄72岁（32 ~ 92岁）。中位OS为28个月（1-83个月），17例（15.45%）转为AML，随访期间死亡94例（85.45%）。最佳临界值为ALC （1.2 × 109/L）、AMC （0 × 109/L）、CRP （6.1 mg/L）、MLR（0.125）、NLR（2.25）、PLR（71.4）。ALC（≤1.2 × 109/L, P = 0.017）、MLR （>0.125, P = 0.01）、PLR （>71.43, P = 0.044）、CRP （>6.1 mg/L, P 0.125, P = 0.011）、CRP （>6.1 mg/L, P = 0.017）水平与预后不良相关。结论：MLR和CRP水平升高可能是新诊断MDS患者预后不良的独立指标。
Association between lymphocyte-associated ratios, C-reactive protein and prognostic value in myelodysplastic syndromes.
Purpose: This study was designed to investigate the relationship between peripheral blood inflammatory markers and prognosis in MDS patients.
Methods: We conducted a study involving 183 MDS patients who were diagnosed at Taizhou Hospital of Zhejiang Province and Enze Hospital between January 2015 and December 2019. The end point of follow-up was September 2022. To minimize the impact of other confounding factors among the 110 included MDS patients, X-tile software was used to determine the optimal cutoff points for peripheral blood inflammation markers. Based on these cutoff points, the cohort of patients was divided into a high-risk group and a low-risk group. The OS in each group was analyzed by the Kaplan-Meier method, and univariate and multivariate Cox regression analyses were employed.
Results: The MDS patients included 73 men and 37 women with a median age of 72 years (32-92 years). The median OS was 28 months (1-83 months), 17 patients (15.45%) experienced conversion to AML, and 94 patients (85.45%) died during the follow-up period. The optimal cutoff points were ALC (1.2 × 109/L), AMC (0 × 109/L), CRP (6.1 mg/L), MLR (0.125), NLR (2.25) and PLR (71.4). Patients in the ALC (≤1.2 × 109/L, P = 0.017), MLR (>0.125, P = 0.01), PLR (>71.43, P = 0.044), and CRP (>6.1 mg/L, P < 0.0001) groups had shorter overall survival. The MLR (>0.125, P = 0.011) and CRP (>6.1 mg/L, P = 0.017) levels were related to poor prognosis.
Conclusions: Elevated MLR and CRP levels may be independent indicators of poor prognosis in newly diagnosed MDS patients.
期刊介绍：
Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
